The health-related, social, and economic consequences of parkinsonism: A controlled national study

Journal of Neurology

Volumn 258, Issue 8, 2011, Pages 1497-1506

  Jennum, Poul ^a   Zoetmulder, Marielle ^a,b   Korbo, Lise ^b   Kjellberg, Jakob ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c Dansk Sundhedsinstitut   (Denmark)

Author keywords

Economic burden; Employment; Health costs; Illness costs; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG COST; EMPLOYMENT STATUS; FEMALE; HEALTH CARE COST; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PARKINSON DISEASE; PARKINSONISM; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SOCIOECONOMICS;

ADULT; AGED; AGED, 80 AND OVER; COST OF ILLNESS; DENMARK; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; YOUNG ADULT;

EID: 79961030492     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-5969-1     Document Type: Article

References (58)

1. MC de Rijk C Tzourio MM Breteler, et al. 1997 Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study European Community Concerted Action on the Epidemiology of Parkinson's disease J Neurol Neurosurg Psychiatry 62 10 15 9010393 10.1136/jnnp.62.1.10 (Pubitemid 27047434)
2. MM Wickremaratchi D Perera C O'Loghlen, et al. 2009 Prevalence and age of onset of Parkinson's disease in Cardiff: a community based cross sectional study and meta-analysis J Neurol Neurosurg Psychiatry 80 805 807 19531689 10.1136/jnnp.2008.162222 1:STN:280:DC%2BD1MvisVGlsg%3D%3D
3. M Yamawaki M Kusumi H Kowa K Nakashima 2009 Changes in prevalence and incidence of Parkinson's disease in Japan during a quarter of a century Neuroepidemiology 32 263 269 19209006 10.1159/000201565
4. EJ Newman KA Grosset DG Grosset 2009 Geographical difference in Parkinson's disease prevalence within West Scotland Mov Disord 24 401 406 19021227 10.1002/mds.22359
5. KF Pedersen JP Larsen G Alves D Aarsland 2009 Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study Parkinsonism Relat Disord 15 295 299 18801696 10.1016/j.parkreldis.2008.07.006
6. D Hirtz DJ Thurman K Gwinn-Hardy M Mohamed AR Chaudhuri R Zalutsky 2007 How common are the "common" neurologic disorders? Neurology 68 326 337 17261678 10.1212/01.wnl.0000252807.38124.a3 1:STN:280:DC%2BD2s%2FlslChug%3D%3D (Pubitemid 46188246)
7. M Guttman PM Slaughter ME Theriault DP DeBoer CD Naylor 2001 Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study Neurology 57 2278 2282 11756610 1:STN:280:DC%2BD38%2Fls1arsQ%3D%3D (Pubitemid 34019205)
8. E Singer 1973 Social costs of Parkinson's disease J Chronic Dis 26 243 254 4714571 10.1016/0021-9681(73)90105-7 1:STN:280:DyaE3s3gslaitA%3D%3D
9. C McRae P Sherry K Roper 1999 Stress and family functioning among caregivers of persons with Parkinson's disease Parkinsonism Relat Disord 5 69 75 18591123 10.1016/S1353-8020(99)00012-7 1:STN:280:DC%2BD1cvitFylsA%3D%3D (Pubitemid 29256371)
10. M Caap-Ahlgren O Dehlin 2002 Factors of importance to the caregiver burden experienced by family caregivers of Parkinson's disease patients Aging Clin Exp Res 14 371 377 12602571 (Pubitemid 36526928)
11. CH Dowding CL Shenton SS Salek 2006 A review of the health-related quality of life and economic impact of Parkinson's disease Drugs Aging 23 693 721 17020395 10.2165/00002512-200623090-00001 (Pubitemid 44536905)
12. KH Karlsen E Tandberg D Arsland JP Larsen 2000 Health related quality of life in Parkinson's disease: a prospective longitudinal study J Neurol Neurosurg Psychiatry 69 584 589 11032608 10.1136/jnnp.69.5.584 1:STN:280: DC%2BD3M%2FivV2gtg%3D%3D
13. A Korchounov G Bogomazov 2006 Employment, medical absenteeism, and disability perception in Parkinson's disease: a pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy Mov Disord 21 2220 2224 17044084 10.1002/mds.21123 (Pubitemid 46140443)
14. A Schrag P Banks 2006 Time of loss of employment in Parkinson's disease Mov Disord 21 1839 1843 16941456 10.1002/mds.21030 (Pubitemid 44848928)
15. A Diem-Zangerl K Seppi GK Wenning E Trinka G Ransmayr W Oberaigner W Poewe 2009 Mortality in Parkinson's disease: a 20 year follow-up study Mov Disord 24 819 825 19224612 10.1002/mds.22414
16. EB Forsaa JP Larsen T Wentzel-Larsen G Alves 2010 What predicts mortality in Parkinson disease? A prospective population-based long-term study Neurology 75 14 1270 1276 20921512 10.1212/WNL.0b013e3181f61311 1:STN:280: DC%2BC3cfnt1KqsA%3D%3D
17. EB Montgomery Jr 2009 Basal ganglia pathophysiology in Parkinson's disease Ann Neurol 65 618 19475660 10.1002/ana.21649 author reply 618-619
18. AL Bartels KL Leenders 2009 Parkinson's disease: the syndrome, the pathogenesis and pathophysiology Cortex 45 915 921 19095226 10.1016/j.cortex. 2008.11.010
19. D Weintraub CL Comella S Horn 2008 Parkinson's disease-part 1: pathophysiology, symptoms, burden, diagnosis, and assessment Am J Manag Care 14 S40 S48 18402507
20. EB Montgomery Jr 2006 Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 67 2266 17190966 10.1212/01.wnl.0000252726.13187.63 author reply 2266
21. CW Olanow MB Stern K Sethi 2009 The scientific and clinical basis for the treatment of Parkinson disease (2009) Neurology 72 S1 S136 19470958 10.1212/WNL.0b013e3181a1d44c
22. AE Lang 2009 When and how should treatment be started in Parkinson disease? Neurology 72 S39 S43 19221313 10.1212/WNL.0b013e318198e177 1:CAS:528:DC%2BD1MXhslygsL4%3D
23. M Stacy A Galbreath 2008 Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia Clin Neuropharmacol 31 51 56 18303491 10.1097/WNF.0b013e318065b088 1:CAS:528:DC%2BD1cXivVOnsL4%3D (Pubitemid 351321441)
24. M Stacy A Galbreath 2008 Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesia Clin Neuropharmacol 31 120 125 18382184 10.1097/WNF.0b013e318065b09c 1:CAS:528:DC%2BD1cXktVCntbw%3D (Pubitemid 351489338)
25. H Braak U Rub WP Gai K Del Tredici 2003 Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen J Neural Transm 110 517 536 12721813 10.1007/s00702-002-0808-2 1:STN:280:DC%2BD3s3gt1GltQ%3D%3D (Pubitemid 36543283)
26. EC Hirsch 2007 How to improve neuroprotection in Parkinson's disease? Parkinsonism Relat Disord 13 S332 S335 18267260 10.1016/S1353-8020(08)70026-9 (Pubitemid 351215264)
27. LJ Findley 2007 The economic impact of Parkinson's disease Parkinsonism Relat Disord 13 Suppl S8 S12 17702630 10.1016/j.parkreldis.2007.06.003 (Pubitemid 47444536)
28. V Fraix JL Houeto C Lagrange, et al. 2006 Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease J Neurol Neurosurg Psychiatry 77 443 449 16543519 10.1136/jnnp.2005.077677 1:STN:280:DC%2BD287lsVWnuw%3D%3D
29. AG Hempel ML Wagner MA Maaty JI Sage 1998 Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations Ann Pharmacother 32 878 883 9762373 10.1345/aph.16353 1:STN:280:DyaK1cvjsFWhsw%3D%3D (Pubitemid 28420324)
30. P Lindgren 2004 Economic evidence in Parkinson's disease: a review Eur J Health Econ 5 Suppl 1 S63 S66 15754076 10.1007/s10198-005-0290-5 (Pubitemid 39440399)
31. K Noyes AW Dick RG Holloway 2004 Pramipexole v levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial Med Decis Making 24 472 485 15358996 10.1177/0272989X04268960 (Pubitemid 39232124)
32. G Wang Q Cheng R Zheng, et al. 2006 Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China Mov Disord 21 1439 1443 16773620 10.1002/mds.20999 (Pubitemid 44613297)
33. Efron B, Tibshirani RJ (1994) An introduction to the bootstrap: (monographs on statistics and applied probablity). Chapman and Hall, London
34. B Goldsworthy S Knowles 2008 Caregiving for Parkinson's disease patients: an exploration of a stress-appraisal model for quality of life and burden J Gerontol B Psychol Sci Soc Sci 63 P372 P376 19092040
35. KS Kim BJ Kim KH Kim, et al. 2007 Subjective and objective caregiver burden in Parkinson's disease Taehan Kanho Hakhoe Chi 37 242 248 17435409
36. P Martinez-Martin S Arroyo JM Rojo-Abuin C Rodriguez-Blazquez B Frades J de Pedro Cuesta 2008 Burden, perceived health status, and mood among caregivers of Parkinson's disease patients Mov Disord 23 1673 1680 18709684 10.1002/mds.22106
37. P Martinez-Martin J Benito-Leon F Alonso, et al. 2005 Quality of life of caregivers in Parkinson's disease Qual Life Res 14 463 472 15892435 10.1007/s11136-004-6253-y (Pubitemid 40576396)
38. A Schrag A Hovris D Morley N Quinn M Jahanshahi 2006 Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls, and disability Parkinsonism Relat Disord 12 35 41 16271496 10.1016/j.parkreldis. 2005.06.011 (Pubitemid 43037151)
39. AE Spottke M Reuter O Machat, et al. 2005 Cost of illness and its predictors for Parkinson's disease in Germany Pharmacoeconomics 23 817 836 16097843 10.2165/00019053-200523080-00007 (Pubitemid 41420428)
40. D Coyle J Oakley 2008 Estimating the expected value of partial perfect information: a review of methods Eur J Health Econ 9 251 259 17638032 10.1007/s10198-007-0069-y (Pubitemid 351962398)
41. K Noyes H Liu H Temkin-Greener 2006 Cost of caring for Medicare beneficiaries with Parkinson's disease: impact of the CMS-HCC risk-adjustment model Dis Manag 9 339 348 17115881 10.1089/dis.2006.9.339 (Pubitemid 44904295)
42. HM Bryson RJ Milne P Chrisp 1992 Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease Pharmacoeconomics 2 118 136 10146952 10.2165/00019053-199202020-00005 1:STN:280:DyaK2cbgvVWntg%3D%3D
43. J Hudry JO Rinne T Keranen L Eckert JM Cochran 2006 Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland Ann Pharmacother 40 651 657 16569799 10.1345/aph.1G454 1:CAS:528: DC%2BD28XkslamsLY%3D
44. M Iskedjian TR Einarson 2003 Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease Pharmacoeconomics 21 115 127 12515573 10.2165/00019053-200321020-00004 (Pubitemid 36127007)
45. K Noyes AW Dick RG Holloway 2007 The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation Med Decis Making 27 327 334 17502449 10.1177/0272989X07301822 (Pubitemid 46801750)
46. CS Palmer MJ Nuijten JK Schmier P Subedi EH Snyder 2002 Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States Pharmacoeconomics 20 617 628 12141889 10.2165/00019053-200220090-00005
47. PD Charles BB Padaliya WJ Newman, et al. 2004 Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs Parkinsonism Relat Disord 10 475 479 15542007 10.1016/j.parkreldis.2004.05.006 (Pubitemid 39489880)
48. E McIntosh A Gray T Aziz 2003 Estimating the costs of surgical innovations: the case for subthalamic nucleus stimulation in the treatment of advanced Parkinson's disease Mov Disord 18 993 999 14502666 10.1002/mds.10481 (Pubitemid 37185206)
49. EA Spottke J Volkmann D Lorenz, et al. 2002 Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus J Neurol 249 759 766 12111311 10.1007/s00415-002-0711-7 1:STN:280:DC%2BD38zms1ygtQ%3D%3D (Pubitemid 34651759)
50. F Valldeoriola O Morsi E Tolosa J Rumia MJ Marti P Martinez-Martin 2007 Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease Mov Disord 22 2183 2191 17724747 10.1002/mds.21652
51. RA Berry JF Murphy 1995 Well-being of caregivers of spouses with Parkinson's disease Clin Nurs Res 4 373 386 7580943 10.1177/105477389500400404 1:STN:280:DyaK28%2FltFOmug%3D%3D
52. Edwards NE, Ruettiger KM (2002) The influence of caregiver burden on patients' management of Parkinson's disease: implications for rehabilitation nursing. Rehabil Nurs 27:182-186, 198
53. S Happe K Berger 2002 The association between caregiver burden and sleep disturbances in partners of patients with Parkinson's disease Age Ageing 31 5 349 354 12242196 10.1093/ageing/31.5.349 (Pubitemid 35174522)
54. SL Reese 2007 Psychosocial factors in Parkinson's disease Dis Mon 53 291 295 17656190 10.1016/j.disamonth.2007.02.006 (Pubitemid 47080991)
55. Teel CS, Press AN (1999) Fatigue among elders in caregiving and noncaregiving roles. West J Nurs Res 21:498-514; discussion 514-420
56. C Vossius OB Nilsen JP Larsen 2009 Parkinson's disease and nursing home placement: the economic impact of the need for care Eur J Neurol 16 194 200 19146640 10.1111/j.1468-1331.2008.02380.x 1:STN:280:DC%2BD1M%2FnsVyisg%3D%3D
57. KK Martikainen TH Luukkaala RJ Marttila 2006 Parkinson's disease and working capacity Mov Disord 21 2187 2191 17183549 10.1002/mds.21171 (Pubitemid 46140434)
58. P Jennum S Knudsen J Kjeldberg 2009 The economic consequences of narcolepsy J Clin Sleep Med 5 240 245 19960645